Get the Stockscreener App
7.87
1.01%
-0.08
After Hours:
7.71
-0.16
-2.03%
Optimizerx Corp stock is traded at $7.87, with a volume of 82,173.
It is down -1.01% in the last 24 hours and up +14.89% over the past month.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
See More
Previous Close:
$7.95
Open:
$7.84
24h Volume:
82,173
Relative Volume:
0.24
Market Cap:
$148.24M
Revenue:
$107.35M
Net Income/Loss:
$6.84M
P/E Ratio:
22.28
EPS:
0.3532
Net Cash Flow:
$14.64M
1W Performance:
-1.01%
1M Performance:
+14.89%
6M Performance:
+0.00%
1Y Performance:
-57.71%
1-Day Range:
$7.66
$7.90
1-Week Range:
$7.48
$8.3499
52-Week Range:
$4.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Name
Optimizerx Corp
Sector
Industry
Phone
248-651-6558
Address
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, BTSG, TEM, TXG, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
7.87 | 149.93M | 107.35M | 6.84M | 14.64M | 0.3532 |
VEEV
Veeva Systems Inc
|
275.09 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.73 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
64.62 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
62.65 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
HQY
Healthequity Inc
|
96.07 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-20-24 | Initiated | Stephens | Equal-Weight |
| Jul-25-24 | Resumed | B. Riley Securities | Buy |
| Apr-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Feb-02-23 | Resumed | B. Riley Securities | Buy |
| Nov-01-22 | Initiated | Stifel | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| Oct-18-21 | Resumed | B. Riley Securities | Buy |
| Apr-13-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-03-19 | Initiated | William Blair | Outperform |
View All
Optimizerx Corp Stock (OPRX) Latest News
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript - AOL.com
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
OptimizeRx (OPRX) Slips to $8.72 as Shares Consolidate Near Range MidpointInverse ETF Flow - vinanet.vn
Optimizerx Stock Price Forecast. Should You Buy OPRX? - StockInvest.us
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
Conferencia de resultados del segundo trimestre fiscal de 2026 de OptimizeRx (OPRX): Reitera previsiones mientras los ingresos caen un 30% - TradingKey
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - marketbeat.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Nigeria
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Earnings Call zu Q2 des Geschäftsjahres 2026: Prognose bestätigt, während der Umsatz um 30 % sinkt - TradingKey
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
Stifel cuts OptimizeRx stock price target on revenue headwinds By Investing.com - Investing.com Australia
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Technology Magazine
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
OptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M - scanx.trade
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO - Investing.com
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO By Investing.com - Investing.com India
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook - Stock Titan
OptimizeRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027 - Stock Titan
OptimizeRx Refinances Debt With $35M Facility, Pays Down $8.3M - Stock Titan
BRIEF-OPTIMIZERx Q2 Revenue USD 20.5 Million Vs. IBES Estimate USD 20.2 Million - Bitget
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside - finance.biggo.com
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside - Yahoo Finance
OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OPRX News | OPTIMIZERX CORP (NASDAQ:OPRX) - ChartMill
OPRX|OptimizeRx Corp|Price:7.080|Chg%:+0.340 - TradingKey
Segall Bryant & Hamill LLC Invests $1.19 Million in OptimizeRx Corp. $OPRX - MarketBeat
OPRX|OptimizeRx Corp|Price:6.575|Chg%:+0.525 - TradingKey
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OptimizeRx Corp (OPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OptimizeRx (OPRX) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET - The Manila Times
OptimizeRx Corp (OPRX) Cash Flow - TradingKey
OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OPRX|OptimizeRx Corp|Price:8.525|Chg%:-0.195 - TradingKey
Optimizerx Corp Stock (OPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Optimizerx Corp Stock (OPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stelmakh Edward | Chief Finance & Strat Officer |
Dec 19 '25 |
Sale |
13.51 |
1,388 |
18,752 |
126,830 |
| Silvestro Stephen L | Chief Executive Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
6,546 |
0 |
195,462 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
3,928 |
0 |
94,526 |
| Besch Doug | Chief Product & Tech Officer |
Dec 19 '25 |
Option Exercise |
0.00 |
1,964 |
0 |
71,536 |
| Odence-Ford Marion | Chief Legal & Admin Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
92,550 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
6,649 |
0 |
190,536 |
| Silvestro Stephen L | Chief Executive Officer |
Oct 03 '25 |
Sale |
18.75 |
1,620 |
30,375 |
188,916 |
| Stelmakh Edward | Chief Finance & Strat Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
16,623 |
0 |
127,387 |
| Besch Doug | Chief Product & Tech Officer |
Oct 03 '25 |
Option Exercise |
0.00 |
3,325 |
0 |
70,555 |
0.03%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):